IDO1 and glioblastoma: The mechanisms by which IDO enhancement may help fight glioblastoma cells are still not clear, and agents acting solely on IDO without simultaneously targeting other immune checkpoints such as PD-L1 are not effective (Ladomersky et al., 2018).